Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-7,073
Closed -$225K 614
2023
Q4
$225K Sell
7,073
-2,066
-23% -$64.9K 0.01% 493
2023
Q3
$322K Buy
9,139
+419
+5% +$16K 0.01% 396
2023
Q2
$331K Sell
8,720
-314
-3% -$12.5K 0.01% 417
2023
Q1
$341K Sell
9,034
-9,336
-51% -$359K 0.02% 408
2022
Q4
$779K Buy
18,370
+7,841
+74% +$323K 0.02% 337
2022
Q3
$338K Buy
10,529
+3,593
+52% +$126K 0.02% 336
2022
Q2
$225K Sell
6,936
-897
-11% -$29.1K 0.02% 398
2022
Q1
$283K Buy
7,833
+1,105
+16% +$37.9K 0.02% 410
2021
Q4
$266K Sell
6,728
-697
-9% -$29.1K 0.01% 484
2021
Q3
$324K Buy
7,425
+923
+14% +$41.4K 0.02% 418
2021
Q2
$265K Sell
6,502
-1,060
-14% -$40.9K 0.01% 478
2021
Q1
$248K Buy
7,562
+178
+2% +$6.69K 0.01% 454
2020
Q4
$300K Sell
7,384
-945
-11% -$35.3K 0.02% 375
2020
Q3
$305K Sell
8,329
-2,162
-21% -$78.2K 0.02% 347
2020
Q2
$356K Sell
10,491
-2,714
-21% -$74K 0.03% 303
2020
Q1
$280K Buy
13,205
+126
+1% +$2.81K 0.03% 304
2019
Q4
$292K Sell
13,079
-6
-0% -$131 0.03% 351
2019
Q3
$265K Buy
+13,085
New +$258K 0.03% 348

Other funds holding GMAB

HBK Sorce Advisory's GMAB Position: Q1 2024 in Review

HBK Sorce Advisory sold out of Genmab (GMAB) in Q1 2024, closing a stake of 7,073 shares — an estimated $225K sold.

HBK Sorce Advisory first reported a position in GMAB in Q3 2019 and held it in 18 quarters. The position peaked at $779K in Q4 2022. 227 funds tracked by Wall St. Rank hold GMAB as of Q1 2024.

  • HBK Sorce Advisory reported no remaining Genmab position as of Q1 2024 after selling out during the quarter.
  • HBK Sorce Advisory sold 7,073 Genmab shares in Q1 2024, an estimated $225K.
  • HBK Sorce Advisory first reported a position in Genmab in Q3 2019 and held it in 18 quarters.
  • HBK Sorce Advisory's Genmab position peaked at $779K in Q4 2022.
  • 227 funds tracked by Wall St. Rank held Genmab as of Q1 2024.

Based on HBK Sorce Advisory's 13F filing for Q1 2024, filed 9 May 2024.